Abstract | IMPORTANCE OF THE FIELD: Despite therapeutic advances, cancer remains the cause of an estimated 23% of deaths in the USA. New treatments for malignancy are greatly needed. AREAS COVERED IN THIS REVIEW: WHAT THE READER WILL GAIN:
Talaporfin sodium has a broad safety profile and a mode of action that could affect growth in treated and untreated tumors. TAKE HOME MESSAGE: Clinical and preclinical studies indicate that talaporfin sodium treatment may offer a powerful option to synergize current therapies, as well as an alternative monotherapy in treating cancer.
|
Authors | S Wang, Elizabeth Bromley, Leon Xu, James C Chen, Llew Keltner |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 1
Pg. 133-40
(Jan 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20001435
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Cancer Vaccines
- Oxides
- Porphyrins
- Talaporfin
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cancer Vaccines
(therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, pathology)
- Clinical Trials, Phase III as Topic
- Colorectal Neoplasms
(drug therapy, immunology)
- Combined Modality Therapy
(methods)
- Humans
- Japan
(epidemiology)
- Liver Neoplasms
(drug therapy, immunology)
- Male
- Neoplasm Staging
- Neoplasms
- Oxides
(metabolism)
- Porphyrins
(therapeutic use)
|